ARS Pharmaceuticals (SPRY) Research & Development (2020 - 2026)

ARS Pharmaceuticals has disclosed Research & Development across 7 years of filings, most recently posting $4.3 million for Q1 2026.

• Research & Development for Q1 2026 came in at $4.3 million, up 46.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.6 million (down 15.8% YoY), and the FY2025 annual result was $13.2 million, down 32.68% from the prior year.
• Research & Development came in at $4.3 million for Q1 2026 at ARS Pharmaceuticals, up from $3.4 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $7.3 million in Q2 2023 to a low of $2.8 million in Q3 2025.
• The 5-year median for Research & Development is $4.3 million (2026), against an average of $4.5 million.
• Peak annual rise in Research & Development reached 118.57% in 2022, while the deepest fall reached 75.49% in 2022.
• ARS Pharmaceuticals' Research & Development stood at $4.7 million in 2022, then fell by 27.73% to $3.4 million in 2023, then declined by 11.08% to $3.0 million in 2024, then increased by 13.74% to $3.4 million in 2025, then climbed by 25.94% to $4.3 million in 2026.
• The last three Research & Development figures came in at $4.3 million (Q1 2026), $3.4 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.